Le réseau international des Instituts Pasteur
Accès gratuit
Numéro
Med Sci (Paris)
Volume 29, Numéro 10, Octobre 2013
Le réseau international des Instituts Pasteur
Page(s) 908 - 911
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20132910020
Publié en ligne 18 octobre 2013
  1. Straetemans M, Bierrenbach AL, Nagelkerke N, et al. The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLoS One 2010 ; 5 : e15241. [CrossRef] [PubMed]
  2. World health organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2003 revision. Geneva : WHO, 2003.
  3. Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002 ; 16 : 75–83. [CrossRef] [PubMed]
  4. Kimerling ME, Schuchter J, Chanthol E, et al. Prevalence of pulmonary tuberculosis among HIV-infected persons in a home care program in Phnom Penh, Cambodia. Int J Tuberc Lung Dis 2002 ; 6 : 988–994. [PubMed]
  5. Eng B, Cain KP, Nong K, et al. Impact of a public antiretroviral program on TB/HIV mortality: Banteay Meanchey, Cambodia. Southeast Asian J Trop Med Public Health 2009 ; 40 : 89–92. [PubMed]
  6. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011 ; 365 : 1471–1481. [CrossRef] [PubMed]
  7. Pean P, Nerrienet E, Madec Y, et al. Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients with tuberculosis. Blood 2012 ; 119 : 3315–3320. [CrossRef] [PubMed]
  8. Chou M, Bertrand J, Segeral O, et al. Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Antimicrob Agents Chemother 2010 ; 54 : 4432–4439. [CrossRef] [PubMed]
  9. Lang TA, White NJ, Hien TT, et al. Clinical research in resource-limited settings: Enhancing research capacity and working together to make trials less complicated. PLoS Negl Trop Dis 2010 ; 4 : e619. [CrossRef] [PubMed]
  10. Blanchard-Horan C, Stocker V, Moran L, et al. Examining the challenges and solutions to the implementation of trials in resource-limited settings: Limited resource trials. Appl Clin Trials 2012 ; 21 : 34–42. [PubMed]
  11. Strauss RP, Sengupta S, Quinn SC, et al. The role of community advisory boards: involving communities in the informed consent process. Am J Public Health 2001 ; 91 : 1938–1943. [CrossRef] [PubMed]
  12. Lo B, Bayer R. Establishing ethical trials for treatment and prevention of AIDS in developing countries. Br Med J 2003 ; 327 : 337–339. [CrossRef] [PubMed]
  13. Borand L, Laureillard D, Madec Y, et al. Plasma concentrations of efavirenz with a 600 mg standard dose in Cambodian HIV-infected adults treated for tuberculosis with a body weight above 50 kg. Antivir Ther 2013 ; 18 : 419–423. [CrossRef] [PubMed]
  14. Breton G. Syndrome inflammatoire de reconstitution immune. Med Sci (Paris) 2010 ; 26 : 281–290. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.